Study spotlights disparities in COVID-19 clinical trials | CIDRAP

A study yesterday in JAMA Internal Medicine shows women and racial minorities were underrepresented in both COVID-19 clinical treatment trials and in disease prevention trials.

The research was conducted by a team from the Fred Hutchinson Cancer Center, as well researchers from Beijing and London.

Many patients with weak immune systems don't realize their Covid-19 medicine isn't as effective as it used to be | CNN Judy Salins considers herself a smart, empowered patient, but until this week, she had no idea that the medicine she takes to defend herself against Covid-19 isn't protecting her as well as it used to. Elizabeth Cohen,Naomi Thomas CNN

...

The medicine is called Evusheld, and its effectiveness is waning dramatically because new Covid-19 subvariants are taking center stage, and the drug doesn’t neutralize all of them.

Time Magazine

The Latest COVID-19 Variants Can Evade Vaccine Protection, According to New Data

New lab data suggest that vaccines and prior infections may not offer enough protection against several new COVID-19 variants cropping up in the U.S. and around the world.

Dr. David Ho, director of Columbia University’s Aaron Diamond AIDS Research Center, and his team reported the results from a set of studies published in the journal Nature. They showed how well some of the latest variants—BQ.1, BQ.1.1, XBB, and XBB.1, which were all derived from Omicron—are evading both vaccine-derived and infection-derived immunity.

...

The Pandemic Uncovered Ways to Speed Up Science There doesn't have to be a trade-off between good research and fast research. Saloni Dattani WIRED

The pandemic highlighted broad problems in research: that many studies were hyped, error-ridden, or even fraudulent, and that misinformation could spread rapidly. But it also demonstrated what was possible.